Atypical Femoral Fracture in Hypophosphatasia: A Systematic Review.
Journal
International journal of endocrinology
ISSN: 1687-8337
Titre abrégé: Int J Endocrinol
Pays: Egypt
ID NLM: 101516376
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
04
2023
revised:
03
08
2023
accepted:
31
08
2023
medline:
21
9
2023
pubmed:
21
9
2023
entrez:
21
9
2023
Statut:
epublish
Résumé
To summarize the characteristics of all reported patients with hypophosphatasia (HPP) who sustained atypical femoral fracture (AFF) and identify all available evidence to quantify the rate of coexistence between HPP and AFF. Potentially eligible articles were identified from the MEDLINE and EMBASE databases from its inception to September 2022, using a search strategy consisting of terms related to "Hypophosphatasia" and "Atypical femoral fracture." Eligible articles must report one of the following information: (1) individual data of patients diagnosed with HPP and AFF, (2) prevalence of HPP among patients with AFF, or (3) prevalence of AFF among patients of HPP. Characteristics of patients reported in each study were extracted. A total of 148 articles were identified. After the systematic review, 24 articles met the eligibility criteria. A total of 28 patients with AFF and HPP were identified. The mean ± SD age of the reported patients was 53.8 ± 12.5 years, and 22 patients (78.6%) were female. Nine patients (32.1%) received antiresorptive medication (bisphosphonate and/or denosumab), and two patients (7.1%) received teriparatide prior to the development of AFF. Seven (25.0%) and eighteen (64.3%) patients sustained unilateral and bilateral AFF, respectively (laterality not reported in three cases). Thirteen patients (46.4%) had a history of fractures at other sites. Four (14.3%) and seven (25.0%) patients received asfotase alfa and teriparatide after sustaining AFF. Two studies reported the prevalence of AFF among patients with HPP of approximately 10%. One study reported one HPP patient in a cohort of 72 patients with AFF. Based on the limited evidence, AFF occurred in up to 10% of patients with HPP. Based on the 28 case reports, about two-thirds did not receive antiresorptive treatment, suggesting that the HPP itself could potentially be a risk factor for AFF.
Identifiants
pubmed: 37731773
doi: 10.1155/2023/5544148
pmc: PMC10508997
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5544148Informations de copyright
Copyright © 2023 Nipith Charoenngam et al.
Déclaration de conflit d'intérêts
The authors declare that they do not have any conflicts of interest.
Références
BMJ Case Rep. 2020 Sep 9;13(9):
pubmed: 32912883
J Bone Metab. 2015 Feb;22(1):1-8
pubmed: 25774358
J Clin Endocrinol Metab. 2007 Apr;92(4):1203-8
pubmed: 17213282
J Biol Chem. 2014 Aug 29;289(35):24168-79
pubmed: 25023282
Joint Bone Spine. 2016 May;83(3):346-8
pubmed: 26992955
N Engl J Med. 2017 May 4;376(18):1794-1795
pubmed: 28467865
JBMR Plus. 2019 Aug 26;3(10):e10223
pubmed: 31687651
Calcif Tissue Int. 2019 Jul;105(1):51-67
pubmed: 31006051
Genes (Basel). 2022 Oct 17;13(10):
pubmed: 36292765
Bone. 2017 Sep;102:15-25
pubmed: 28238808
JBMR Plus. 2018 Jan 03;2(1):1-11
pubmed: 30283886
Endocr Pract. 2022 Oct;28(10):1072-1077
pubmed: 35964860
Calcif Tissue Int. 2022 Jun;110(6):703-711
pubmed: 35229197
Endocrinol Diabetes Metab Case Rep. 2021 Sep 01;2021:
pubmed: 34515659
J Clin Endocrinol Metab. 2010 Mar;95(3):1007-12
pubmed: 20089612
Clin Cases Miner Bone Metab. 2009 Sep;6(3):266-9
pubmed: 22461258
Osteoporos Int. 2018 Aug;29(8):1815-1825
pubmed: 29774402
Endocr Rev. 2019 Apr 1;40(2):333-368
pubmed: 30169557
J Bone Miner Res. 2018 Dec;33(12):2091-2098
pubmed: 30184270
N Engl J Med. 2007 May 3;356(18):1809-22
pubmed: 17476007
J Bone Miner Res. 2012 May;27(5):987-94
pubmed: 22322541
Curr Opin Support Palliat Care. 2012 Sep;6(3):348-54
pubmed: 22643705
Ther Adv Musculoskelet Dis. 2020 Aug 21;12:1759720X20916983
pubmed: 32913448
Am J Med. 1957 May;22(5):730-46
pubmed: 13410963
Acta Orthop. 2017 Jun;88(3):351-353
pubmed: 28077015
J Bone Miner Metab. 2021 Jul;39(4):598-605
pubmed: 33404770
Lancet Diabetes Endocrinol. 2017 Jul;5(7):513-523
pubmed: 28546097
N Engl J Med. 2009 Aug 20;361(8):756-65
pubmed: 19671655
Clin Case Rep. 2022 Mar 27;10(3):e05633
pubmed: 35356190
Joint Bone Spine. 2018 May;85(3):365-367
pubmed: 29246529
BMC Musculoskelet Disord. 2016 Aug 09;17:332
pubmed: 27507156
CMAJ. 2017 Apr 10;189(14):E542
pubmed: 28396331
Bone Rep. 2020 Jan 24;12:100247
pubmed: 32025537
Clin Cases Miner Bone Metab. 2017 Sep-Dec;14(3):347-353
pubmed: 29354166
J Bone Joint Surg Am. 1986 Sep;68(7):981-90
pubmed: 3745261
Curr Opin Pediatr. 2020 Aug;32(4):560-573
pubmed: 32692054
JBMR Plus. 2018 May 17;2(5):304-307
pubmed: 30283912
J Clin Densitom. 2020 Jul - Sep;23(3):340-348
pubmed: 30655187
J Clin Endocrinol Metab. 2010 Dec;95(12):5174-9
pubmed: 20739387
N Engl J Med. 2016 Oct 20;375(16):1583-1584
pubmed: 27641359
J Bone Miner Res. 2014 Jan;29(1):1-23
pubmed: 23712442